Mr. Ben Ward reports

MARICANN EXPANDS EUROPEAN MANAGEMENT TEAM AND PROVIDES CLINICAL TRIAL UPDATE

Maricann Group Inc. has provided the following update with regard to the company's European operations.

Given the rapid expansion of the European medical cannabis market, the recent additions to Maricann's European management team and the expanded ability to complete medical testing in Europe, Maricann now intends to centre its medical cannabis research and development operations in Germany.

Maricann has also added Morten Lars Brandt in the role of general manager, Europe. Mr. Brandt is an experienced pharmaceutical executive, with a broad range of experience in progressively senior roles at life sciences company, Norgine; including vice-president, medium-sized markets, vice-president and general manager. Mr. Brandt is based in Germany and will be spearheading Maricann's pharmaceutical division in Europe.

In addition to Mr. Brandt, Maricann has engaged Dr. Thoralf Schlosser as its qualified person for its European medical division. Dr. Schlosser has held a series of progressively senior roles at Catalent Pharma Solutions, Schorndorf, Dynavax Technologies Europe, Dusseldorf, Sandoz and Rudolstadt, a division of Novartis, as head of quality assurance. Dr. Schlosser received his doctorate of pharmacy from the Studium de Parmazie, University of Leipzig.

Maricann has received its EudraCT (European Union drug-regulating authority clinical trial) number and protocol code number for its pharmacokinetic study to examine the potential increase in bioavailability of cannabinoids using its exclusive patented VesiSorb technology. The company expects to commence studies under the leadership of Dr. Markus Backmund, an advisory board member of Maricann GmbH, and Dr. Steven Bennett, chief scientific officer of Maricann Group.

"Maricann continues to advance its position as a leader in the European medicinal cannabis market, adding to its depth of experience in the pharmaceutical sector with Morten Brandt and Dr. Thoralf Schlosser. Our receipt of our EudraCT number means we can advance and now prove the value of the VesiSorb acquisition as fact," stated Ben Ward, chief executive officer of Maricann Group.

With the appointment of Dr. Schlosser, Dr. Thomas Klumpp has resigned from his full-time position of qualifed person due to personal health reasons. The company is grateful for Dr. Klumpp's assistance, including his work to achieve EU-GMP (Good Manufacturing Practice) status for its initial Canadian cultivation and processing operation, and the time leading up to its inspection of its Maricann GmbH narcotics licensing in Germany. Dr. Klumpp remains available to the company when needed.

About Maricann Group Inc.

Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Burlington, Ont., Canada, and Munich, Germany, with production facilities in Langton, Ont., where it operates a medicinal cannabis cultivation, extraction, formulation and distribution business under federal licence from the government of Canada. The company also has production operations in Dresden, Saxony, Germany and Regensdorf, Switzerland. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a 942,000-square-foot/87,515-square-metre buildout and will continue to pursue new opportunities in Europe.

We seek Safe Harbor.